Incyte (INCY)
(Delayed Data from NSDQ)
$53.06 USD
-0.44 (-0.82%)
Updated May 10, 2024 04:00 PM ET
After-Market: $53.00 -0.06 (-0.11%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
INCY 53.06 -0.44(-0.82%)
Will INCY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for INCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INCY
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
Incyte (INCY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
INCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
Other News for INCY
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Incyte (INCY) and Ventyx Biosciences (VTYX)
The 3 Best Biotech Stocks to Buy in May 2024
5 Low-Debt Stocks for the 'Higher for Longer' Era
Incyte to Present at Upcoming Investor Conference
Incyte’s Resilient Demand and Strong Financials Justify Buy Rating Despite Q1 Sales Dip